Ipamorelin is a synthetic peptide that nudges the pituitary to release growth hormone. It was trialled by pharma for post-operative ileus, failed to win approval and was dropped. Today it is sold only as a research chemical and used off-label in wellness clinics, and it is banned at all times in tested sport by WADA.
CJC-1295 is a synthetic copy of growth hormone–releasing hormone (GHRH), engineered to last in the body for days rather than minutes. It was tested in early human trials in the mid-2000s, abandoned by its developer, and now circulates only as a research chemical. It is not an approved medicine anywhere, and is banned at all times in tested sport by WADA.
Ipamorelin sits at grade C; CJC-1295 at grade D. On evidence alone, Ipamorelin is the safer recommendation. That said, "stronger evidence" doesn't always mean "right for you", read both pages, then talk to a clinician.
The one indication ipamorelin reached human trials for. A randomised, placebo-controlled phase 2 study in bowel-resection patients (Beck et al. 2014) reported some signal on gastric motility but missed its primary endpoint. Development was halted.
Reliably raises GH in animals and healthy volunteers in short-duration studies. Whether sustained micro-pulses translate to meaningful long-term clinical outcomes in humans is not established.
The Teichman 2006 Phase I trial established that a single dose raises GH and IGF-1 for several days. This is a pharmacokinetic finding, not a clinical outcome, no approved indication followed.
ConjuChem ran a Phase II trial for fat-redistribution in HIV-positive patients. The trial was halted in 2006 after a patient death; development of CJC-1295 was effectively abandoned soon after.
Widely used off-label in bodybuilding circles, often stacked with ipamorelin or other GH secretagogues. No controlled human trial has tested body-composition endpoints.
In short-duration human trials ipamorelin was generally well tolerated, with the most common reports being injection-site reactions, mild headache and transient flushing. Longer-term safety in healthy adults using it for performance or anti-ageing reasons is unknown, there are no multi-month controlled trials in this population. Chronic stimulation of the GH/IGF-1 axis is the main theoretical concern: it could in principle worsen insulin resistance, drive water retention, accelerate diabetic retinopathy, or promote the growth of pre-existing tumours (IGF-1 is mitogenic). People with active cancer, a cancer history, diabetes, or who are pregnant or breastfeeding should not use it. Products sold as "ipamorelin" online are unregulated research chemicals, purity, sterility and dose-per-vial vary, and contamination is a real risk.
The safety profile in humans is essentially unknown. The Teichman Phase I trial reported headache, flushing, and injection-site reactions as the commonest dose-related adverse events. The class as a whole, GH secretagogues, is associated with reduced insulin sensitivity, raised blood glucose, and fluid retention at doses that meaningfully raise IGF-1, all of which are concerns for long-term, unsupervised use. There is also a well-recognised theoretical risk that sustained IGF-1 elevation could promote the growth of existing tumours; this has not been demonstrated for CJC-1295 specifically but is a standard caution across the GH/IGF-1 axis.
A single trial-participant death occurred during the 2006 ConjuChem lipodystrophy Phase II study; the attending physician's judgement was that the death (asymptomatic coronary disease with plaque rupture) was most likely unrelated to CJC-1295, but the study was halted and the programme was effectively abandoned shortly after. Online lore that has grown around this, including reports of unexplained deaths in users in subsequent years, is poorly documented and causation has not been established. We mention it because it is part of the public record, not because the link is proven.
Ipamorelin sits at grade C; CJC-1295 at grade D. On evidence alone, Ipamorelin is the safer recommendation. That said, "stronger evidence" doesn't always mean "right for you", read both pages, then talk to a clinician.
Pepwyse comparison pages are generated from the same structured data behind each peptide profile. Want a different head-to-head? Use the compare picker or ask Ipamorelin directly via the Ask-Peppy button. Not medical advice, see how we grade evidence.